Compare Honest Company Inc (HNST) vs Tempus AI (TEM) Price & Performance

HNST trades at $3.87, up 1.04% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.01, meeting estimates, but has missed expectations in two of the last three quarters. Revenue declined to $371.32 million in 2025 from $378 million in 2024, with a net loss of $15.69 million. Positive cash flow from operations of $15.12 million and record gross margins near 34% highlight operational improvements amid challenges.

The outlook remains mixed; analyst consensus is cautious with 30% buy ratings. Upside potential exists from gross margin expansion and cost controls, but risks include persistent net losses, competitive pressures in personal care, and reliance on retail channel growth. Investor sentiment is neutral, pending sustained profitability and revenue stabilization in 2026.

Tempus AI (TEM) trades at $48.41, down 7.74% in the last 24 hours, reflecting a bearish technical signal. The company reported revenue of $1.27 billion in 2025 but a net loss of $245.03 million, with negative profitability metrics. Recent news highlights growth in AI-driven diagnostics and data services, including FDA approvals and research collaborations. The stock is trading well below the analyst consensus price target of $68.50, with a majority of analysts maintaining a Buy rating.

The outlook for TEM is a mix of high growth potential in healthcare AI and significant financial risk due to persistent losses. Investment opportunity lies in its proprietary data platform and expanding market reach, but risks include execution challenges and cash burn. Wall Street sentiment remains positive on long-term prospects, but investors should weigh the volatility against the company's unproven path to profitability.